Valneva partners with Oxford Immunotec on T cell analysis for COVID-19 vaccine
Valneva has chosen UK-based diagnostics company Oxford Immunotec to perform T cell testing on participants receiving its COVID-19 vaccine candidate (VLA2001) in a Phase I/II study.
Valneva’s VLA2001-201 study is designed to investigate the safety, tolerability and immunogenicity of its inactivated SARS-CoV-2 virus vaccine in healthy subjects.
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 test will evaluate if vaccination with Valneva’s vaccine candidate induces a T cell response in study participants.
In previous studies, Oxford Immunotec’s test has demonstrated that SARS-CoV-2 responsive T cell numbers were associated with protection from COVID-19.
The aim of collecting T cell data from the VLA2001-201 study is to potentially gather additional information for assessing the efficacy of Valneva’s COVID-19 vaccine candidate.
Read more: http://www.pharmatimes.com/news/valneva_partners_with_oxford_immunotec_on_t_cell_analysis_for_covid-19_vaccine_1361243
Valneva’s VLA2001-201 study is designed to investigate the safety, tolerability and immunogenicity of its inactivated SARS-CoV-2 virus vaccine in healthy subjects.
Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 test will evaluate if vaccination with Valneva’s vaccine candidate induces a T cell response in study participants.
In previous studies, Oxford Immunotec’s test has demonstrated that SARS-CoV-2 responsive T cell numbers were associated with protection from COVID-19.
The aim of collecting T cell data from the VLA2001-201 study is to potentially gather additional information for assessing the efficacy of Valneva’s COVID-19 vaccine candidate.
Read more: http://www.pharmatimes.com/news/valneva_partners_with_oxford_immunotec_on_t_cell_analysis_for_covid-19_vaccine_1361243
